| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Trea | Phase III | rekrutiert |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Trea | Phase III | rekrutiert |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carbopla | Phase III | rekrutiert |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet | Phase III | rekrutiert |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab a | Phase III | rekrutiert |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in P | Phase III | rekrutiert |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapse | Phase III | rekrutiert |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembroliz | Phase III | rekrutiert |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin | Phase III | rekrutiert |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combi | Phase III | rekrutiert |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab P | Phase III | rekrutiert |
| Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At | Phase II | rekrutiert |
| Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected St | Phase III | rekrutiert |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase III | rekrutiert |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD | Phase III | rekrutiert |
| DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig P | Phase III | rekrutiert |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung | Phase II | rekrutiert |
| Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With | Phase III | rekrutiert |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive | Phase III | rekrutiert |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanc | Phase III | rekrutiert |
| Post-Market BTVA Registry | — | rekrutiert |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for P | Phase III | rekrutiert |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Inve | Phase II / Phase III | rekrutiert |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-sm | Phase II / Phase III | rekrutiert |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resect | Phase III | rekrutiert |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants W | Phase II | rekrutiert |
| TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study | — | rekrutiert |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | Phase III | rekrutiert |
| The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysem | ohne Phasenangabe | rekrutiert |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plu | Phase III | rekrutiert |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Seco | Phase III | rekrutiert |